Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Fifty Day Moving Average – Should You Sell?
by Renee Jackson · The Cerbat GemDyadic International Inc. (NASDAQ:DYAI – Get Free Report)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.93 and traded as low as $0.90. Dyadic International shares last traded at $0.90, with a volume of 21,630 shares trading hands.
Analysts Set New Price Targets
A number of research firms recently issued reports on DYAI. HC Wainwright initiated coverage on Dyadic International in a report on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dyadic International currently has an average rating of “Hold” and a consensus price target of $3.00.
Read Our Latest Stock Analysis on DYAI
Dyadic International Price Performance
The company has a market cap of $32.57 million, a PE ratio of -3.75 and a beta of 1.26. The stock has a fifty day moving average price of $0.93 and a 200-day moving average price of $0.98. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85.
Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.22 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. On average, equities analysts expect that Dyadic International Inc. will post -0.18 earnings per share for the current year.
Institutional Investors Weigh In On Dyadic International
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Marathon Capital Management acquired a new stake in shares of Dyadic International during the 3rd quarter valued at about $41,000. Bank of America Corp DE raised its position in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares in the last quarter. AlphaCore Capital LLC acquired a new stake in Dyadic International in the second quarter valued at approximately $50,000. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the 3rd quarter valued at $190,000. Finally, Truist Financial Corp lifted its stake in shares of Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the last quarter. 27.95% of the stock is owned by hedge funds and other institutional investors.
Dyadic International Company Profile
Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.
The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.